IP Library › Granted Patent US 12,275,771
Granted Patent B2
US 12,275,771 · App. 17/458,136 · Granted Apr 15, 2025

Relaxin immunoglobulin fusion proteins and methods of use

Inventors: Feng Wang (Carlsbad, CA); Yan Liu (San Diego, CA); Ying Wang (San Diego, CA); Guangsen Fu (San Diego, CA); Peter G. Schultz (La Jolla, CA)
Assignee: THE SCRIPPS RESEARCH INSTITUTE
C07K14/64A61K9/0019A61K9/0048A61K9/02A61K9/10A61P11/00A61P13/12C07K16/1027A61K38/00A61K2039/505A61K2039/54A61K2039/545C07K2317/24C07K2317/52C07K2317/565C07K2317/732C07K2317/76C07K2317/92C07K2317/94C07K2319/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,275,771
App. No.
17/458,136
Granted
Apr 15, 2025
Kind
B2
Abstract

Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.

Claims (31)

1. An antibody comprising a light chain comprising light chain complementarity determining regions CDRL1, CDRL2, and CDRL3, and a heavy chain comprising heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein:

the CDRL1 comprises the amino acid sequence of SEQ ID NO: 89 (KCQLSVGYMH),

the CDRL2 comprises the amino acid sequence of SEQ ID NO: 90 (DTSKLAS),

the CDRL3 comprises the amino acid sequence of SEQ ID NO: 96 (FQGNGYPFT),

the CDRH1 comprises the amino acid sequence of SEQ ID NO: 72 (TFSGFSLSTSGMSVG),

the CDRH2 comprises the amino acid sequence of SEQ ID NO: 73 (DIWWDDKKDYNPSLKS),

and the CDRH3 comprises the amino acid sequence of SEQ ID NO: 79 (SMITFGGFDV).

2. The antibody of claim 1 , wherein the light chain comprises a sequence at least 90% identical to SEQ ID NO: 12.

3. The antibody of claim 1 , wherein the heavy chain comprises a sequence at least 90% identical to SEQ ID NO: 16.

4. The antibody of claim 1 , wherein—the light chain comprises a sequence at least 90% identical to SEQ ID NO: 12, and the heavy chain comprises a sequence at least 90% identical to SEQ ID NO: 16.

5. The antibody of claim 1 , wherein the light chain comprises SEQ ID NO: 12, and the heavy chain comprises SEQ ID NO: 16.

6. A composition comprising a relaxin polypeptide connected to the antibody of claim 1 .

7. The composition of claim 6 , wherein the relaxin polypeptide is connected to the amino-terminus of the antibody.

8. The composition of claim 6 , wherein the relaxin polypeptide comprises a B chain and an A chain.

9. The composition of claim 8 , wherein the B chain comprises SEQ ID NO: 46.

10. The composition of claim 8 , wherein the A chain comprises SEQ ID NO: 45.

11. The composition of claim 8 , wherein the B chain comprises SEQ ID NO: 46, and the A chain comprises SEQ ID NO: 45.

12. The composition of claim 6 , wherein the relaxin polypeptide comprises a sequence at least 90% identical to-SEQ ID NO: 49.

13. The composition of claim 6 , wherein the heavy chain sequence comprises SEQ ID NO: 22.

14. A composition comprising a first polypeptide comprising a relaxin polypeptide connected to the amino-terminus of a heavy chain antibody variable domain, and a second polypeptide comprising a light chain antibody variable domain, wherein;

i) the heavy chain variable domain is at least 90% identical to SEQ ID NO: 16 and comprises heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein the CDRH1 comprises the amino acid sequence of SEQ ID NO: 72 (TFSGFSLSTSGMSVG), the CDRH2 comprises the amino acid sequence of SEQ ID NO: 73 (DIWWDDKKDYNPSLKS), and the CDRH3 comprises an amino acid sequence selected from SEQ ID NO: 79 (SMITFGGFDV), SEQ ID NO: 80 (SMITNAYFDV), and SEQ ID NO: 81 (SMITNGYFDV); and

ii) the light chain antibody variable domain is at least 90% identical to SEQ ID NO: 12 and comprises light chain complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein the CDRL1 comprises the amino acid sequence of SEQ ID NO: 89 (KCQLSVGYMH), wherein the CDRL2 comprises the amino acid sequence of SEQ ID NO: 90 (DTSKLAS) and wherein the CDRL3 comprises an amino acid sequence selected from SEQ ID NO: 91 (FOGSGYPFT), SEQ ID NO: 95 (FOYSGYPFT), and SEQ ID NO: 96 (FOGNGYPFT); and

wherein the heavy chain antibody variable domain and the light chain antibody variable domain form an immunoglobulin domain that binds to RSV F protein; wherein the relaxin polypeptide comprises a B chain comprising SEQ ID NO: 46, and an A chain comprising SEQ ID NO: 45.

15. The composition of claim 14 , wherein the relaxin polypeptide comprises a sequence at least 90% identical to SEQ ID NO: 49.

16. The composition of claim 14 , wherein the first polypeptide comprises SEQ ID NO: 22 and the second polypeptide comprises SEQ ID NO: 12.

17. The composition of claim 14 , wherein the heavy chain variable domain is at least 95% identical to SEQ ID NO: 16, and the light chain antibody variable domain is at least 95% identical to SEQ ID NO: 12.

18. The composition of claim 14 , wherein the first polypeptide comprises SEQ ID NO: 22 and the second polypeptide comprises SEQ ID NO: 10.

19. The composition of claim 14 , wherein the first polypeptide comprises SEQ ID NO: 22 and the second polypeptide comprises SEQ ID NO: 11.

20. The composition of claim 14 , wherein the first polypeptide comprises SEQ ID NO: 20 and the second polypeptide comprises SEQ ID NO: 10.

21. The composition of claim 14 , wherein the first polypeptide comprises SEQ ID NO: 20 and the second polypeptide comprises SEQ ID NO: 11.

22. The composition of claim 14 , wherein the first polypeptide comprises SEQ ID NO: 20 and the second polypeptide comprises SEQ ID NO: 12.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2022
From: WANG, FENG; WANG, YING; SCHULTZ, PETER G.; LIU, YAN; FU, GUANGSEN
To: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH
Reel/Frame 059508/0733 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2022
From: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 059508/0739 →
Continuity (3)
Continuation 16060384
Provisional Application 62265344 · Dec 9, 2015
Related Publication 20220048969A1 · Feb 17, 2022
References Cited (106)
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 5911997A · Schwabe et al. · 1999 [cited by applicant]
US 6211147B1 · Unemori · 2001 [cited by applicant]
US 6372716B1 · Bush et al. · 2002 [cited by applicant]
US 6566329B1 · Meyn et al. · 2003 [cited by applicant]
US 6685940B2 · Andya et al. · 2004 [cited by applicant]
US 6723702B2 · Conrad et al. · 2004 [cited by applicant]
US 6740747B2 · Kaushik et al. · 2004 [cited by applicant]
US 6780836B2 · Unemori · 2004 [cited by applicant]
US 6984128B2 · Breining et al. · 2006 [cited by applicant]
US 7553813B2 · Unemori · 2009 [cited by applicant]
US 7878978B2 · Conrad et al. · 2011 [cited by applicant]
US 8026215B2 · Unemori · 2011 [cited by applicant]
US 8053411B2 · Unemori et al. · 2011 [cited by applicant]
US 8372809B2 · Unemori et al. · 2013 [cited by applicant]
US 8415301B2 · Unemori et al. · 2013 [cited by applicant]
US 8602998B2 · Conrad et al. · 2013 [cited by applicant]
US 9644021B2 · Wang et al. · 2017 [cited by applicant]
US 10683353B2 · Wang et al. · 2020 [cited by applicant]
US 10774132B2 · Smider et al. · 2020 [cited by applicant]
US 11161891B2 · Wang et al. · 2021 [cited by applicant]
US 20020164326A1 · Young et al. · 2002 [cited by applicant]
US 20040192606A1 · Unemori · 2004 [cited by applicant]
US 20040266685A1 · Conrad et al. · 2004 [cited by applicant]
US 20050186526A1 · Stewart et al. · 2005 [cited by applicant]
US 20060159695A1 · Delvecchio et al. · 2006 [cited by applicant]
US 20060247172A1 · Unemori · 2006 [cited by applicant]
US 20060257918A1 · Ramanathan et al. · 2006 [cited by applicant]
US 20060269892A1 · Breining et al. · 2006 [cited by applicant]
US 20070293485A1 · Lim et al. · 2007 [cited by applicant]
US 20080108572A1 · Unemori · 2008 [cited by applicant]
US 20080260731A1 · Bernett et al. · 2008 [cited by applicant]
US 20100041603A1 · Stewart · 2010 [cited by applicant]
US 20110144019A1 · Unemori et al. · 2011 [cited by applicant]
US 20110166070A1 · Stewart et al. · 2011 [cited by applicant]
US 20110245469A1 · Wang · 2011 [cited by applicant]
US 20110293513A1 · Govindan et al. · 2011 [cited by applicant]
US 20130053318A1 · Laura et al. · 2013 [cited by applicant]
US 20130116181A1 · Unemori et al. · 2013 [cited by applicant]
US 20130210730A1 · Unemori et al. · 2013 [cited by applicant]
US 20140005112A1 · Unemori et al. · 2014 [cited by applicant]
US 20140057832A1 · Conrad et al. · 2014 [cited by applicant]
US 20140066377A1 · Parry et al. · 2014 [cited by applicant]
US 20140148390A1 · Haupts et al. · 2014 [cited by applicant]
US 20140187491A1 · Wilmen et al. · 2014 [cited by applicant]
US 20140227267A1 · Wang et al. · 2014 [cited by applicant]
US 20150011431A1 · Smider et al. · 2015 [cited by applicant]
US 20160237156A1 · Wang et al. · 2016 [cited by applicant]
US 20170327577A1 · Wang et al. · 2017 [cited by applicant]
US 20190263882A1 · Wang et al. · 2019 [cited by applicant]
AU 2012211451A1 · 2012 [cited by applicant]
EP 0133988A2 · 1985 [cited by applicant]
EP 2311882A1 · 2011 [cited by applicant]
WO WO9315722A1 · 1993 [cited by applicant]
WO WO9420069A1 · 1994 [cited by applicant]
WO WO0103737A1 · 2001 [cited by applicant]
WO WO0164751A2 · 2001 [cited by applicant]
WO WO0164751A3 · 2001 [cited by applicant]
WO WO0243660A2 · 2002 [cited by applicant]
WO WO0243660A3 · 2003 [cited by applicant]
WO WO2009140659A2 · 2009 [cited by applicant]
WO WO2009140661A1 · 2009 [cited by applicant]
WO WO2010108153A2 · 2010 [cited by applicant]
WO WO2012169822A2 · 2012 [cited by applicant]
WO WO2012170977A1 · 2012 [cited by applicant]
WO WO2014059213A1 · 2014 [cited by applicant]
WO WO2015006744A1 · 2015 [cited by applicant]
WO WO2018013483A1 · 2018 [cited by applicant]
Wu et al. JMB 2005, vol. 350, pp. 126-144 (Year: 2005). [cited by examiner]
Hu et al., Nature Nanotechnology, vol. 16, pp. 466-477 (Year: 2021). [cited by examiner]
Crelin (Science, vol. 164(3875):81-2 (Year: 1969). [cited by examiner]
Becker, J.C. et al. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. USA 93:7826-7831 (Jul. 1996). [cited by applicant]
Casset et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communication 307:198-205 (2003). [cited by applicant]
Colman et al., Effects of amino acid sequence changes on antibody-antigen interactions, Research in Immunology, 1994; 145(1):33-36. [cited by applicant]
Eppstein et al. Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. Proc. Natl. Acad. Sci. USA, 82: 3688-3692 (1985). [cited by applicant]
Gillies, Stephen D. A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity. Protein Engineering, Design & Selection 26(10)… [cited by applicant]
Holzer, W. et al. A Fusion Protein of IL-8 and a FAB Antibody Fragment Binds to IL-8 Receptors and Induces Neutrophil Activation. CYTOKINE, 8(3):214-221 (Mar. 1996). [cited by applicant]
International Application No. PCT/US16/65779 International Search Report and Written Opinion Mailed May 31, 2017. [cited by applicant]
International Application No. PCT/US2015/034533 International Preliminary Report on Patentability Mailed Dec. 15, 2016. [cited by applicant]
International Application No. PCT/US2016/065779 International Preliminary Report on Patentability Mailed Jun. 21, 2018. [cited by applicant]
Langer et al. Biocompatibility of polymeric delivery systems for macromolecules. J Biomed Mater Res 15(2):267-277 (Mar. 1981). [cited by applicant]
LeFleur, D.W. et al. Monoclonal antibody therapeutics with up to five specificities Funtional enhancement through fusion of target-specific peptides. mAbs 5(2):208-218 (Mar./Apr. 2013). [cited by applicant]
Lu, D. et al. Construction and Production of an IgG-Like Tetravalent Bispecific Antibody, IgG-Single-Chain Fv Fusion. Human Monoclonal Antibodies: Methods and Protocols, Methods in Molecular Biology, vol. 1060, Chapter … [cited by applicant]
Pardridge, W.M. and Boado, R. Pharmacokinetics and Safety in Rhesus Monkeys of a Monoclonal Antibody-GDNF Fusion Protein for Targeted Blood-Brain Barrier Delivery. Pharmaceutical Research, 26(10):2227-2236 (Oct. 2009). [cited by applicant]
Paul, W.E. Fundamental Immunology, Third Edition (textbook). “Fv Structure and Diversity in Three Dimensions” pp. 292-295; Raven Press, New York (1993). [cited by applicant]
Reusch et al. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. Int J Ca… [cited by applicant]
Rudikoff et al.: Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. 79(6):1979-83 (1982). [cited by applicant]
Saini, et al. Exceptionally long CDR3H region with multiple cysteine residues in functional bovine IgM antibodies. Eur J Immunol. Aug. 1999;29(8):2420-2426. [cited by applicant]
Schlapschy, et al. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng Des Sel. Jun. 2007;20(6):273-84. Epub Jun. 26, 2… [cited by applicant]
Sidman et al. Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid. Biopolymers, 22(1): 547-556 (Jan. 1983). [cited by applicant]
U.S. Appl. No. 16/060,384 Non-Final Office Action dated Feb. 19, 2021. [cited by applicant]
U.S. Appl. No. 16/060,384 Final Office Action dated Jul. 23, 2020. [cited by applicant]
U.S. Appl. No. 16/060,384 Non-Final Office Action dated Jan. 17, 2020. [cited by applicant]
U.S. Appl. No. 16/060,384 Restriction Requirement dated Sep. 6, 2019. [cited by applicant]
Vugmeyster, Y. et al. Pharmacokinetics of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions in mice. International Immunopharmacology 18:225-227 (2014). [cited by applicant]
Wang, et al., Reshaping Antibody Diversity. Cell 153: 1379-1393 (2013). [cited by applicant]
Weidle, U.H. et al. Genetically Engineered Fusion Proteins for Treatment of Cancer. Cancer Genomics & Proteomics 9:357-372 (2012). [cited by applicant]
Wu; et al., “Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Track”, JMP Science Direct, Feb. 24, 2007, 368, 652-665. [cited by applicant]
Wu; et al., “Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and Binding Valence on Viral Neutralization”, JMB Science Direct, Apr. 2005, 350, 126-144. [cited by applicant]
Wu, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. Nov. 2007;25(11): 1290-7. Epub Oct. 14, 2007. [cited by applicant]
Yang et al. Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery. PNAS 113(15):4140-4145 (2016). [cited by applicant]
“Ye, T. et al. High-Level expression and characterization of an anti-VEGF165 single-chain variable fragment (scFv) by small ubiquitin-related modifier fusion in [cited by applicant]
Yi, K.S. et al. Expression System for Enhanced Green Flourescence Protein Conjugated Recombinant Antibody Fragment. Hybridoma and Hybridomics, 23(5):279-286 (2004). [cited by applicant]
Zhang, et al. An Antibody with a Variable-Region Coiled-Coil Knob: Domain. Angew. Chem. Int. Ed. 53: 132-135 (2014). [cited by applicant]
Zhang, et al., Functional Antibody CDR3 fusion proteins with enhanced pharmacological properties. Angew. Chem. Int. Ed. 52: 8295-8298 (2013). [cited by applicant]
Zhang et al., Rational Design of Humanized Dual-Agonist Antibodies. J. Am. Chem. Soc. 137: 38-41 (2015). [cited by applicant]